Liposomal Bupivacaine Interscalene Nerve Block in Shoulder Arthroplasty

Overview

About this study

The purpose of this study is to determine if peripheral nerve block with liposomal bupivacaine in combination with standard bupivacaine will prolong the duration of block, improve pain scores, and decrease opioid utilization in the post-operative period when compared to peripheral nerve block with standard bupivacaine alone.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

All adult patients (>18 years of age).
Patients undergoing standard or reverse total shoulder arthroplasty for the primary diagnoses of glenohumeral arthritis or cuff tear arthropathy.
Cognitively intact with the ability to give informed consent as outlined by our institutional review board.
Patients must be capable of participating in the post-operative electronic survey and / or able to maintain a written diary of events.

Exclusion Criteria

Non-elective cases.
Infection, tumor, trauma.
Weight < 50 kg.
Patients with any contraindications to regional anesthesia including allergy or hypersensitivity to amide-type local anesthetics.
Patients with allergy to any component of medication regimen e.g. amide-type local anesthetics, oxycodone, hydromorphone, fentanyl.
Chronic pain patients with history of chronic opioid use (defined as 20 mg morphine equivalent / day for greater than 30 days pre-operatively.
Concurrent painful physical condition that may require analgesic treatment that is not related to the shoulder surgery (chronic peripheral neuropathy, radiculopathy, or other neurologic disorder).
Severe hepatic disease defined by elevated liver function tests above normal.
Pregnancy.
Respiratory disease that contraindicates interscalene nerve block (elevated contralateral hemidiaphragm, contralateral pneumonectomy, or severe COPD with FEV1 < 50% predicted, and 02 dependence).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Steven Hattrup, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Steven Hattrup, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials